A detailed history of Kaizen Financial Strategies transactions in Abb Vie Inc. stock. As of the latest transaction made, Kaizen Financial Strategies holds 3,994 shares of ABBV stock, worth $680,377. This represents 0.47% of its overall portfolio holdings.

Number of Shares
3,994
Previous 3,977 0.43%
Holding current value
$680,377
Previous $682,000 15.54%
% of portfolio
0.47%
Previous 0.44%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$163.84 - $199.33 $2,785 - $3,388
17 Added 0.43%
3,994 $788,000
Q2 2024

Aug 02, 2024

BUY
$154.79 - $180.76 $96,124 - $112,251
621 Added 18.5%
3,977 $682,000
Q1 2024

May 02, 2024

BUY
$159.82 - $182.1 $57,375 - $65,373
359 Added 11.98%
3,356 $611,000
Q4 2023

Jan 18, 2024

BUY
$137.6 - $154.97 $51,324 - $57,803
373 Added 14.21%
2,997 $464,000
Q3 2023

Oct 31, 2023

SELL
$133.59 - $154.65 $30,592 - $35,414
-229 Reduced 8.03%
2,624 $391,000
Q2 2023

Aug 07, 2023

SELL
$132.51 - $164.9 $3,047 - $3,792
-23 Reduced 0.8%
2,853 $384,000
Q1 2023

May 10, 2023

BUY
$144.61 - $166.54 $433 - $499
3 Added 0.1%
2,876 $458,000
Q4 2022

Jan 18, 2023

BUY
$138.31 - $165.87 $276 - $331
2 Added 0.07%
2,873 $0
Q3 2022

Oct 18, 2022

SELL
$134.21 - $153.93 $12,615 - $14,469
-94 Reduced 3.17%
2,871 $385,000
Q2 2022

Jul 18, 2022

BUY
$137.62 - $174.96 $2,614 - $3,324
19 Added 0.64%
2,965 $454,000
Q1 2022

May 06, 2022

SELL
$131.98 - $163.75 $23,228 - $28,820
-176 Reduced 5.64%
2,946 $478,000
Q4 2021

Jan 26, 2022

SELL
$107.43 - $135.93 $42,864 - $54,236
-399 Reduced 11.33%
3,122 $423,000
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $9,469 - $10,749
-89 Reduced 2.47%
3,521 $380,000
Q1 2021

May 28, 2021

SELL
$102.3 - $112.62 $332,372 - $365,902
-3,249 Reduced 47.37%
3,610 $391,000
Q4 2020

Feb 03, 2021

BUY
$80.49 - $108.67 $552,080 - $745,367
6,859 New
6,859 $735,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Kaizen Financial Strategies Portfolio

Follow Kaizen Financial Strategies and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kaizen Financial Strategies, based on Form 13F filings with the SEC.

News

Stay updated on Kaizen Financial Strategies with notifications on news.